Ruocong Zhao

Shenzhen University — China

Medicine · Health Sciences

14h-index943citations33works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(23), Immune Cell Function and Interaction(11), Cancer Immunotherapy and Biomarkers(7), Immunotherapy and Immune Responses(7), Virus-based gene therapy research(5)

Publications33 total

CAR-T cell exhaustion in B cell lymphoma: Current status, mechanisms, and potential solutions
Molecular Therapy Oncology·2025Open Access
Adoptive T-cell therapy targeting a novel non-canonical neoantigen derived from a translated AML1-ETO lncrna shows clinical activity in a first-in-human trial for t(8;21) AML
Blood·2025Open Access
Insufficient S-sulfhydration of cAMP-response element binding protein 1 participates in hyperhomocysteinemia or cisplatin induced kidney fibrosis via promoting epithelial-mesenchymal transition
Free Radical Biology and Medicine·2025· 2 cited
Correction: Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells
Journal of Hematology & Oncology·2025· 1 citedOpen Access
The high efficacy of claudin18.2-targeted CAR-T cell therapy in advanced pancreatic cancer with an antibody-dependent safety strategy
Molecular Therapy·2025· 6 citedOpen Access
Informal Institutions and the Investment-Financing Maturity Mismatch in Chinese Enterprises: An Analysis from the Perspective of Strategic Alliances
SSRN Electronic Journal·2025Open Access
Disruption of CISH promotes the antitumor activity of human T cells and decreases PD-1 expression levels
Molecular Therapy — Oncolytics·2022· 30 citedOpen Access
CD318 is a target of chimeric antigen receptor T cells for the treatment of colorectal cancer
Clinical and Experimental Medicine·2022· 11 cited
Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis
Nature Communications·2022· 40 citedOpen Access
Correction to: BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
Cell Death and Disease·2022· 2 citedOpen Access
BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
Cell Death and Disease·2022· 57 citedOpen Access
DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D
Molecular Therapy — Oncolytics·2022· 16 citedOpen Access
The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies
Frontiers in Immunology·2022· 13 citedOpen Access
Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer
Frontiers in Immunology·2021· 58 citedOpen Access
IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells
Leukemia·2020· 47 cited
Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth
Biomarker Research·2020· 65 citedOpen Access
Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth
2020· 1 citedOpen Access
Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth
2020· 1 citedOpen Access
PSCA is a target of chimeric antigen receptor T cells in gastric cancer
Biomarker Research·2020· 40 citedOpen Access
Current status and hurdles for CAR-T cell immune therapy
Blood Science·2019· 10 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Peng Li(24), Qiting Wu(18), Yao Yao(17), Yangqiu Li(14), Youguo Long(13), Xinru Wei(10), Pentao Liu(10), Le Qin(10), Xuchao Zhang(9), Simiao Lin(8), Zhaoyang Tang(8), Duanqing Pei(8), Yi‐Long Wu(8), Diwei Zheng(7), Zhenfeng Zhang(7), Yunxin Lai(7), Zhiwu Jiang(7), Suna Wang(7), Wei Wei(7), Jiang Lv(6)